[go: up one dir, main page]

MX2014004968A - Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma. - Google Patents

Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.

Info

Publication number
MX2014004968A
MX2014004968A MX2014004968A MX2014004968A MX2014004968A MX 2014004968 A MX2014004968 A MX 2014004968A MX 2014004968 A MX2014004968 A MX 2014004968A MX 2014004968 A MX2014004968 A MX 2014004968A MX 2014004968 A MX2014004968 A MX 2014004968A
Authority
MX
Mexico
Prior art keywords
asthma
severity
reducing
methods
acute exacerbations
Prior art date
Application number
MX2014004968A
Other languages
English (en)
Inventor
Nestor Molfino
Joseph Parker
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2014004968A publication Critical patent/MX2014004968A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporcionan métodos para reducir el número y la gravedad de exacerbaciones agudas de asma en un paciente con asma, que comprende administrar a un paciente con un historial de exacerbaciones agudas de asma una cantidad eficaz de un anticuerpo anti-receptor de interleucina 5 (IL-5R) o un fragmento de unión al antígeno de este, por ejemplo, un anticuerpo anti-IL-5Ra o un fragmento de unión al antígeno de este, p. ej., benralizumab.
MX2014004968A 2011-11-01 2012-10-28 Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma. MX2014004968A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161554110P 2011-11-01 2011-11-01
US201161562544P 2011-11-22 2011-11-22
US201261645699P 2012-05-11 2012-05-11
PCT/US2012/062349 WO2013066780A2 (en) 2011-11-01 2012-10-28 Methods for reducing the frequency and severity of acute exacerbations of asthma

Publications (1)

Publication Number Publication Date
MX2014004968A true MX2014004968A (es) 2014-08-01

Family

ID=48193002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004968A MX2014004968A (es) 2011-11-01 2012-10-28 Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.

Country Status (11)

Country Link
US (1) US20140328839A1 (es)
EP (1) EP2773374A4 (es)
JP (1) JP2014533246A (es)
KR (1) KR20140097217A (es)
CN (1) CN104039352A (es)
AU (1) AU2012332859A1 (es)
CA (1) CA2853858A1 (es)
HK (2) HK1201440A1 (es)
MX (1) MX2014004968A (es)
RU (1) RU2014122189A (es)
WO (1) WO2013066780A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
PT3520811T (pt) * 2013-08-12 2021-03-15 Astrazeneca Ab Métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumabe
ES2901634T3 (es) 2013-08-12 2022-03-23 Astrazeneca Ab Métodos para mejorar los síntomas de asma mediante el uso de benralizumab
SG11201600481UA (en) * 2013-08-12 2016-02-26 Medimmune Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
CN113350278B (zh) * 2013-10-24 2023-03-24 阿斯利康(瑞典)有限公司 稳定的水性抗体配制品
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
RU2734490C2 (ru) 2014-11-14 2020-10-19 Санофи Байотекнолоджи Способы лечения хронического синусита с полипами носа путем введения антагониста il-4r
US20160272706A1 (en) * 2015-01-12 2016-09-22 Medimmune Limited Il-13 binding proteins and uses thereof
EP3305321B1 (en) * 2015-06-01 2024-10-16 University of Toyama Therapeutic agent and therapeutic method for pulmonary hypertension
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN111100210B (zh) * 2019-01-30 2022-04-19 武汉九州钰民医药科技有限公司 一种Fc融合蛋白及其应用
AU2020315369A1 (en) 2019-07-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing asthma by administering an IL-4R antagonist
TW202214692A (zh) 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010354A1 (fr) * 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US20050226867A1 (en) * 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
KR101827179B1 (ko) * 2007-05-14 2018-02-07 아스트라제네카 아베 호염기구 수준을 감소시키기 위한 의약

Also Published As

Publication number Publication date
HK1201440A1 (en) 2015-09-04
WO2013066780A2 (en) 2013-05-10
US20140328839A1 (en) 2014-11-06
EP2773374A4 (en) 2015-04-29
HK1200088A1 (en) 2015-07-31
CA2853858A1 (en) 2013-05-10
EP2773374A2 (en) 2014-09-10
AU2012332859A1 (en) 2014-05-22
JP2014533246A (ja) 2014-12-11
WO2013066780A3 (en) 2013-07-04
CN104039352A (zh) 2014-09-10
KR20140097217A (ko) 2014-08-06
RU2014122189A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2014004968A (es) Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
MX347164B (es) Anticuerpos anti-il-36r.
MX342240B (es) Anticuerpos anti-fgfr4 y metodos de uso.
MX2018010572A (es) Inmunoglobulinas heterodimericas.
MX350311B (es) Anticuerpos anti-phf-tau y sus usos.
WO2013064701A3 (en) Specific antibodies and their isolation with anti-idiotypic antibodies
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
PH12014500904B1 (en) Antibody formulations and methods
TN2012000555A1 (en) Antibodies to human gdf8
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
MX2013009362A (es) Anticuerpo contra el csf-1r.
SG10201807042YA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
GB201114858D0 (en) Anti-nerve growth factor antibodies and methods of using the same
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
MX2013009151A (es) Inmunoterapia mejorada.
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201491286A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
EP3170892A4 (en) Method for enhancing activity of laminin fragment cell culture substrate
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
SG10201807318RA (en) Methods for treating chronic obstructive pulmonary disease using benralizumab
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.